Incidence of extrapyramidal symptoms has been evaluated across short-term studies

Short-term (13-week) study design

Results from a double-blind, randomized, placebo-controlled, fixed-dose, 13-week study of adult inpatients experiencing an acute exacerbation of schizophrenia. Patients were randomized to receive placebo or a 234-mg deltoid injection initiation dose on Day 1, followed by a 39-mg, 156-mg, or 234-mg dose in either the deltoid or gluteal muscle on Day 8, and once-monthly thereafter.

Additional short-term study outcomes

• Pooled data from two 13-week, double-blind studies showed that the overall percentages of EPS-related adverse events were 10% in the placebo group and 12%, 11%, and 11% in the INVEGA SUSTENNA^® 39-mg, 78 mg, and 156-mg groups, respectively.^1,3-5
• In a 9-week, double-blind study, the incidence of parkinsonism and akathisia was higher in the INVEGA SUSTENNA^® 156-mg group (18% and 11%, respectively) than in the INVEGA SUSTENNA^® 78-mg group (9% and 5%, respectively) and placebo group (7% and 4%, respectively).^1,3,5
• The results across all phases of the maintenance trial exhibited comparable findings.¹